Double Fusion of SV2B-ALK and EML4-ALK in Lung Cancer
Author Information
Author(s): Chen Huang, Zhang Menglan, Bai Liyan, Niu Yun, Wang Xiaowei, Jiang Ruiying, Wang Ye, Feng Qianqian, Wang Bei, Dai Tingli, Yuan Mingming, Chen Rongrong, Qi Yujuan, Zhong Dingrong
Primary Institution: China-Japan Friendship Hospital, Beijing, China
Hypothesis
Can a patient with both SV2B-ALK and EML4-ALK fusions respond to alectinib treatment?
Conclusion
The patient with a novel SV2B-ALK and EML4-ALK double-fusion showed a significant response to alectinib treatment.
Supporting Evidence
- The patient had a progression-free survival of over 14 months after starting alectinib.
- Two ALK rearrangements were identified in the patient's tumor tissue.
- The patient had multiple metastases, including to the brain.
Takeaway
A man with lung cancer had two special gene changes and got better after taking a medicine called alectinib.
Methodology
The patient's tumor was analyzed using DNA-based next-generation sequencing to identify gene fusions.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
47-year-old Chinese male with a 30 pack-year smoking history.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website